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Background: The elderly population is rapidly growing, and there is limited
evidence for the use of statins for primary prevention of Atherosclerotic
Cardiovascular Disease (ASCVD) in this population.
Objective: The primary outcome of this study was a composite of the patient’s
first cardiovascular event, defined as cardiovascular death, non-fatal Myocardial
Infarction (MI) or non-fatal stroke (Three Point Major Adverse Cardiovascular
Events: 3P-MACE).
Methods: This retrospective study examined the effect of statin therapy for
primary prevention of cardiovascular outcomes in patients at least 75 years of
age on moderate to high-intensity statin therapy.
Results: A total of 1853 patients were included in this study. Patients were more
likely to experience the composite endpoint if they were in the statin group
compared to the control group (19.7% versus 13.2%, p=0.0004). Patients in
the statin group were significantly more likely to have a non-fatal MI or stroke
compared to the control group (3.2% versus 0.5%, p<0.0001 and 14.1% versus
10.4%, p=0.0193). Patients with diabetes were less likely to die from any cause
if they received statin therapy when compared to the control group (19.18% vs.
43.58%, p<0.0001).
Conclusion: In conclusion, statin therapy appears to be beneficial in elderly
patients with diabetes. However, the same therapy was found to have no benefits
against the primary composite endpoint in this population of patients.
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Background
Globally and nationally, Cardiovascular Disease (CVD) is the number one
cause of death. Nearly 801,000 deaths in America-or 1 out of 3 deaths-each
year can be attributed to CVD [1]. In 2015, approximately 17.7 million
people died from CVD, accounting for 31% of all global deaths [2]. This
is despite constant efforts to combat Major Adverse Cardiovascular Events
(MACE) over the past several decades. Though partially due to modifiable
risk factors, such as smoking, physical inactivity, poor diet, and obesity, age
is also a robust predictor of CVD. In 2013, approximately 80% of deaths
due to coronary heart disease in the United States occurred in people age
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65 years and older [3]. The relationship between CVD risk
and age is of concern, especially considering the anticipated
growth in the elderly population. Projections illustrate that
the population of people over 65 years old in the United
States is expected to increase from 13.7% to 20.3% between
2012 and 2030. More specifically, those over the age of 75
years are expected to nearly double in percentage in that
same timeframe, going from 19.1 million people in 2012 to
34.2 million people in 2030 [4]. As the elderly population
grows, diagnoses of CVD and cardiovascular-related deaths are
projected to increase. The medications collectively known as
“statins” (3-Hydroxy-3-Methyl-Glutaryl Coenzyme A (HMGCoA) reductase inhibitors) are commonly recommendedfor
the treatment of dyslipidemia and the prevention of CVD.
Many studies have been done with this class of medications,
demonstrating the efficacy of statins for primary and secondary
prevention of Atherosclerotic Cardiovascular Disease (ASCVD)
[5]. However, in most of these studies, the elderly population
was frequently excluded, thus yielding a lack of basis for how
to properly treat elderly patients. Trials that did include, and
sometimes focus on, the elderly population and the use of
statins, such as the PROSPER and SAGE trials, often only
evaluated their use for secondary prevention of ASCVD [6,7].
Fortunately, these trials both showed that statins do reduce
cardiovascular risk in elderly individuals with a history of prior
ASCVD. However, whether this benefit exists for the primary
prevention of ASCVD in elderly individuals without prior
ASCVD could not be extrapolated from these studies. Other
trials, such as CARDS and JUPITER, examined the use of
statins for primary prevention of ASCVD in elderly patients
and demonstrated a significant reduction in the incidence
of Myocardial Infarction (MI), Coronary Heart Disease
(CHD) death, revascularization, and unstable angina [8,9].
Unfortunately, these trials typically evaluated patients with
mean ages between 65 and 75 years and rarely evaluated statin
use for primary prevention in patients over the age of 75 years
[7,8]. The age threshold of 75 years is particularly important
when interpreting the various dyslipidemia guidelines that have
published and adopted throughout the world. The most recent
guideline published for the management of dyslipidemia in the

United States, a collaboration between the American College of
Cardiology (ACC) and the American Heart Association (AHA)
in 2018, recommends moderate-intensity statin therapy for
patients over the age of 75 years with ASCVD [10]. However,
for those over 75 years old without prior ASCVD and a 10year CVD risk greater than 7.5%, no recommendations are
provided. The 2017 guidelines published by the American
Association of Clinical Endocrinologists (AACE) and the
American College of Endocrinology (ACE), recommends
that individuals over 75 years old with ASCVD risk factors
be screened for dyslipidemia and treated to goal LDL-C and
non-HDL-C [11]. The 2014 US Department of Veteran
Affairs/Department of Defense (VA/DOD) guidelines do
not provide specific guidance for the elderly population only
noting that all patients with greater than 6% risk for CVD
in the next ten years receive a moderate-intensity statin [12].
Due to the rapidly growing elderly population in the United
States and abroad, as well as the limited evidence for the use of
statins for primary prevention of ASCVD in elderly patients,
it is apparent that more research is warranted in this area.
In this study, we have evaluated the impact of moderate to
high-intensity statin therapy for primary CVD prevention in
patients over 75 years of age.

Methods
This retrospective study was conducted in a Veterans Affairs
Medical Center. The study complied with the Declaration of
Helsinki and the International Conference on Harmonization/
Good Clinical Practice Guidelines and was approved by the
on-site VAMC Institutional Review Board (IRB).
The study examined the effect of statin therapy for primary
prevention of cardiovascular outcomes in patients at least
75 years of age on moderate to high-intensity statin therapy
compared to a control group (Table 1). The primary outcome
of this study was a composite of the patient’s first cardiovascular
event, defined as cardiovascular death, non-fatal MI or non-fatal
stroke (3P-MACE). Secondary endpoints included evaluation
of each of the composite endpoints individually, as well as,
all-cause mortality.

High

Moderate

Atorvastatin 40mg-80mg

Atorvastatin 10mg -20mg

Rosuvastatin 20mg-40mg

Low

Rosuvastatin 5mg-10mg
Simvastatin 10mg -40mg

Simvastatin 10mg

Pravastatin 40mg -80mg

Pravastatin 10mg-20mg

Lovastatin 40mg -80mg

Lovastatin 20mg

Fluvastatin 80mg

Fluvastatin 20mg-40mg

Table 1: Statin Intensity Daily Dose.
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Inclusion criteria included: age of at least 75 years and a
prescription for moderate to high-intensity statin therapy for
three or more consecutive years during the five-year study
period (2012-2017) for the treatment group while those in
the control group did not have an active prescription for a
moderate or high-intensity therapy during the study period.
Also, all patients had to have diagnosis of at least one ASCVD
risk factor in addition to age, such as hypertension, diabetes
mellitus, dyslipidemia, or current smoking status. Patients were
excluded from the study if they had a diagnosis of unstable
angina or prior ASCVD, as defined by the ACC/AHA, at the
beginning of the study period [10].
A five-year study period was chosen to allow adequate time to
analyze the rate of cardiovascular outcomes in each group given
trials evaluating the cardiovascular benefit of statin therapy
illustrated cardiovascular outcomes in similar follow-up time.
In order to provide a statistical power of 80% to detect a
35% difference (a small effect size of 0.27) in the 3P-MACE
occurrence between statin-treated patients and patients not
receiving statin therapy with a two-sided significance level
and an alpha of 0.05, 226 cardiovascular events were necessary
(nQuery Advisor, Statistical Solutions Ltd, Boston, MA).
Patients were further sub-grouped based on their status of
diabetes (Control = 296 with diabetes and 998 without diabetes;

Discovery Software (SAS Institute, Cary, NC) was used for
the statistical analysis.

Results
A total of 1853 patients were included in this study; this
included every eligible patient identified in the electronic health
record. Patients were either on moderate or high-intensity statin
therapy (n=559) or not receiving a moderate or high-intensity
statin (n=1294). Baseline characteristics are noted in table 2.
There were fewer patients with diabetes in the control group
compared to the statin group (p<0.0001). About 39% of the
patients in the control group had a diagnosis of dyslipidemia,
while approximately 72% of those in the statin group had
dyslipidemia diagnoses (p<0.0001). The patients in the
statin group had a higher Body Mass Index (BMI) (25.6 vs.
26.8) (p<0.0001). Moreover, age was statistically greater in the
control group (80.8 vs. 79.4 years) (p<0.0001).
Patients were more likely to experience the composite endpoint
(CV death, non-fatal stroke or non-fatal MI) if they were in
the statin group compared to the control group (19.7% versus
13.2%, p=0.0004) as illustrated in table 3. Further, patients
in the statin group were significantly more likely to have a
non-fatal MI or stroke compared to the control group (3.2%
versus 0.5% p<0.0001 and 14.1% versus 10.4% p=0.0193),
respectively. All-cause mortality in the control group was

Characteristic

Control Group (1294)

Statin Group (559)

Age mean (SD)

80.81 (4.04)

79.42 (3.55) †

Male gender n (%)

1265 (97.8)

546 (97.7)

Caucasian race (n) (%)

1230 (95.1)

543 (97.1)

Diagnosis of dyslipidemia n (%)

507 (39.2)

401 (71.7) †

Diagnosis of hypertension n (%)

1112 (86)

476 (85.1)

Diagnosis of diabetes n (%)

296 (22.9)

219 (39.2) †

Diagnosis of current smoking n (%)

136 (10.5)

46 (8.1)

BMI mean (SD)

25.64 (4.75)

26.82 (4.49) †

Table 2: Baseline Characteristics of Statin and Control Groups.
†Statistically significant difference between control and statin group
BMI: Body Mass Index; n: Number; SD: Standard Deviation

statin = 219 with diabetes and 340 without diabetes). A
nominal logistic regression analysis was appliedto the data with
Group (i.e., treatment vs. control) and Diabetes Status being
the regressors. The model also contained an interaction term
between the two regressors. A p-value < 0.05 was considered
significant. The data were further analyzed using a Chisquare test to examine the difference (in the % of patients
experiencing the end-point) in the end-points between the two
groups concerning patients with diabetes only. JMP Statistical

observed at a rate more than double of that in the statin group
(35.6% vs. 17.5%, p<0.0001).
The sub-group analysis detailed in table 4 revealed patients
diagnosed with diabetes had a higher all-cause mortality
compared to patients without diabetes regardless of the
treatment. However, there was a higher percentage of patients
with diabetes experiencing death in the control group versus
patients without diabetes in the same group (43.58% vs.
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33.27%, p=0.0011). This difference between patients with and
without diagnoses of diabetes with respect to death was not
observed in the statin group (19.18% vs. 16.47%, p=0.4112).

of patients experienced MI in the statin group as opposed to
that in the control group (3.65% vs. 1.01%, p=0.0405). Statin
therapy was not protective concerning the primary composite
endpoint (p=0.0839).
Control Group
(n=1294)

Statin Group
(n=559)

p value

Composite CV death, non-fatal stroke, non-fatal MI n (%)

171 (13.2)

110 (19.7)

0.0004

CV death n (%)

43 (3.4)

23 (4.1)

0.3988

Non-fatal MI n (%)

7 (0.5)

18 (3.2)

<0.0001

Non-fatal stroke n (%)

134 (10.4)

79 (14.1)

0.0193

All-cause mortality n (%)

461 (35.6)

98 (17.5)

<0.0001

Table 3: ASCVD Outcomes and All-Cause Mortality.
ASCVD: Atherosclerotic Cardiovascular Disease; CV: Cardiovascular; MI: Myocardial Infarction; n: Number
Composite CV death, non-fatal stroke, non-fatal MI (%)
Control Group (n=1294)
DM

Non-DM

0.1655

0.1222

p value
0.0534

Statin Group (n=559)
DM

Non-DM

0.21

0.1882

p value

p value
overalla

p value
diabetesb

0.5266

0.0047

0.0839

p value

p value
overalla

p value
diabetesb

0.3855

0.6254

0.1059

p value

p value
overalla

p value
diabetesb

0.6417

0.0002

0.2011

p value

p value
overalla

p value
diabetesb

0.6101

0.0659

0.2033

p value

p value
overalla

p value
diabetesb

0.4112

<0.0001

0.0178

CV death (%)
Control Group
DM

Non-DM

0.0473

0.0291

p value
0.1242

Statin Group
DM

Non-DM

0.0502

0.0353
Non-fatal MI (%)

Control Group
DM

Non-DM

0.0101

0.004

p value
0.2069

Statin Group
DM

Non-DM

0.0365

0.0294

Non-fatal stroke (%)
Control Group
DM

Non-DM

0.125

0.0972

p value
0.1679

Statin Group
DM

Non-DM

0.1507

0.1353

All-Cause Mortality in Sub-Group Analysis
Control Group
DM

Non-DM

0.4358

0.3327

p value
0.0011

Statin Group
DM

Non-DM

0.1918

0.1647

Table 4: ASCVD Outcomes and All-Cause Mortality in Sub-Group Analysis.
DM: Diabetes Mellitus
a
Control versus statins overall, regardless of diabetes diagnosis
b
Diabetes versus non-diabetes overall, regardless of control or statin

Further, the data analysis found that statin therapy was beneficial
in preventing death in patients with diabetes. Patients with
diabetes were less likely to diefrom any cause if they received
statin therapy when compared to the control group (19.18%
vs. 43.58%, p<0.0001), however, a slightly higher percentage
Submit Manuscript

Discussion
The benefits of statin therapy in middle-aged patients at risk
for cardiovascular disease or with a history of cardiovascular
disease is well-established. However, utilizing statins for
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primary prevention in elderly patients remains a topic of
debate. This study showed that in older patients, specifically at
least 75 years of age there is potentially an all-cause mortality
benefit for patients taking moderate or high intensity statins
for at least three years. However, in the absence of diabetes,
moderate to high-intensity statin therapy may not be beneficial
in reducing the first occurrence of cardiovascular disease or
death. In patients diagnosed with diabetes, statin therapy
remained a beneficial pharmacological therapy in preventing
all cause-mortality, however, did not provide a significant
reduction in the primary outcome. Given the higher risk of
mortality in diabetes, the benefits of statin therapy as it relates
to mortality may be worth exploring further. In the absence
of diabetes and a history of the established cardiovascular
disease, however, this study remains to offer up any benefit for
pharmacological intervention as a means to prevent CV death,
non-fatal MI or non-fatal stroke. Potential limitations of the
study include its retrospective nature and subsequent reliance on
appropriate electronic health record coding. There were noted
statistically significant differences in baseline characteristics.
However, not all are presumed to be clinically significant
(i.e., an age difference of 1.4 years and BMI difference of
1.2kg/m2). It was not surprising to see significantly more
patients diagnosed with diabetes and dyslipidemia on statin
therapy as that follows recommendations from numerous
clinical practice guidelines owing to higher atherosclerotic
risks related to the pathophysiology of those diseases. Finally,
patients in the control group could have been taking a low
intensity statin or a moderate or high intensity statin with less
than 80% adherence.
Safety was not evaluated in this trial but is another important
aspect of future studies, specifically prospective designed trials,
and warrants thorough discussion with patients falling in this
age group at risk of cardiovascular disease.
The recently published guidelines by ACC/AHA for the
management of dyslipidemia provide some insight into statin
use in the elderly; however, only a few of the cited articles
specifically address the population of 65 years and older [10].
A sub-analysis in ALLHAT-LTT of patients at least 75 years of
age revealed no significant difference in coronary heart disease
events, stroke or all-cause mortality between patients prescribed
pravastatin 40mg daily versus usual care [13]. In contrast, a
meta-analysis of the JUPITER and HOPE-3 trials showed that
in patients at least 70 years of age taking rosuvastatin 10 or
20mg the composite endpoint of non-fatal MI, non-fatal stroke
and cardiovascular death was significantly reduced compared
to placebo [14]. Age limitations are not explicitly stated in the
VA DoD Clinical Practice Guidelines that note, “for primary
prevention, we recommend a moderate dose statin as the agent

of choice” with strong strength of recommendation. Evidenced
by this trial and others, the favoring for or against statin therapy
in elderly patients is not answered simply and requires a more
in-depth analysis of reason to trial and potential risks.
In conclusion, statin therapy appears to be beneficial in elderly
patients with diabetes. However, the same therapy was found
to have no benefits against the primary composite endpoint
in this population of patients (i.e., primary CVD prevention
in patients over 75 years of age).
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